Sever Pharma Solutions, a leading Contract Development and Manufacturing Organization (CDMO) specializing in controlled release systems for high potent drugs, today announced an expanded agreement with Silo Pharma, Inc. (Nasdaq: SILO), a biopharmaceutical company developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments. Under the new agreement, Sever Pharma Solutions will scale up extrusion processes and continue analytical testing for Silo’s investigational SP-26 ketamine-loaded polymer implant targeting chronic pain and fibromyalgia.
Sever Pharma Solutions has previously supported Silo in earlier development stages of the ketamine implants and successfully validated the delivery system through extensive long-term in-vitro release testing and drug product characterization. The expanded collaboration will enable further pre-clinical development of SP-26, focusing on refining time-released, dose-controlled formulations essential for the implant’s therapeutic efficacy and safety profile.
“We are pleased to continue our collaboration with Sever Pharma Solutions as we move forward with further pre-clinical testing of our novel non-opioid chronic pain therapeutic”, says Silo Pharma’s CEO Eric Weisblum.
“This project together with Silo Pharma exemplifies our commitment to leveraging our specialized capabilities in polymer-based drug delivery systems to help bring novel, non-opioid treatment options closer to patients in need”, says Tony Listro, VP, Technology and Site Lead of Sever Pharma Solutions’ Putnam, CT USA facility.
SP-26 is designed as an injectable, dissolvable subcutaneous implant that delivers controlled doses of ketamine hydrochloride over time, potentially offering a safer and more consistent alternative for managing chronic pain. If clinically successful, SP-26 could qualify for the FDA’s streamlined 505(b)(2) regulatory pathway for drug approval.
For media inquiries, please contact:
Ulrike (Uli) Foley, Head of Global Business Development and Marketing
Email: ufoley@severpharmasolutions.com
For more information about Sever Pharma Solutions, visit www.severpharmasolutions.com
Sever Pharma Solutions is one of the few CDMOs specializing in controlled release systems for highly potent drugs, offering end-to-end services. The company's expertise encompasses the development of new products across various stages of development and the manufacturing of commercial products. Sever Pharma Solutions specializes in Polymer-based sustained release dosage forms such as rings and implants, aseptic Fill and Finish of High Potent drug products, and Hot Melt Extrusion as a solubility enhancement solution for poorly soluble drugs.
Note: This press release is for informational purposes only and does not constitute an endorsement or promotion of any specific product or service
